Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences

G. W. Santos, R. Saral, W. H. Burns, H. G. Braine, L. L. Sensenbrenner, J. R. Wingard, Andrew M Yeager, R. Jones, R. F. Ambinder, S. D. Rowley, S. May, G. B. Vogelsang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56%), 16/30 (53%) and 4/17 (24%), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (NALL) following busulfan (Bu) resulted in DFS and CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56%) and 19/61 (31%) for ages 21-46. Three relapses of 47 (6%) were seen in CR1 and 6/41 (15%) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41%) for 1-67 months (median 15 months). Twenty patients with prior risk non-Hodgkin's lymphoma received 4-HC-purged marrow following Cy + TBI. DFS was 10/20 (50%) for 1.4-9.5 years (median 2.9 years).

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalActa Haematologica
Volume78
Issue numberSUPPL. 1
StatePublished - 1987
Externally publishedYes

Fingerprint

Baltimore
Autologous Transplantation
Disease-Free Survival
Lymphoma
Leukemia
Cyclophosphamide
Bone Marrow
Recurrence
Busulfan
Whole-Body Irradiation
Transplants
Acute Myeloid Leukemia
Survivors
Autografts
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Santos, G. W., Saral, R., Burns, W. H., Braine, H. G., Sensenbrenner, L. L., Wingard, J. R., ... Vogelsang, G. B. (1987). Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences. Acta Haematologica, 78(SUPPL. 1), 175-180.

Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences. / Santos, G. W.; Saral, R.; Burns, W. H.; Braine, H. G.; Sensenbrenner, L. L.; Wingard, J. R.; Yeager, Andrew M; Jones, R.; Ambinder, R. F.; Rowley, S. D.; May, S.; Vogelsang, G. B.

In: Acta Haematologica, Vol. 78, No. SUPPL. 1, 1987, p. 175-180.

Research output: Contribution to journalArticle

Santos, GW, Saral, R, Burns, WH, Braine, HG, Sensenbrenner, LL, Wingard, JR, Yeager, AM, Jones, R, Ambinder, RF, Rowley, SD, May, S & Vogelsang, GB 1987, 'Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences', Acta Haematologica, vol. 78, no. SUPPL. 1, pp. 175-180.
Santos GW, Saral R, Burns WH, Braine HG, Sensenbrenner LL, Wingard JR et al. Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences. Acta Haematologica. 1987;78(SUPPL. 1):175-180.
Santos, G. W. ; Saral, R. ; Burns, W. H. ; Braine, H. G. ; Sensenbrenner, L. L. ; Wingard, J. R. ; Yeager, Andrew M ; Jones, R. ; Ambinder, R. F. ; Rowley, S. D. ; May, S. ; Vogelsang, G. B. / Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences. In: Acta Haematologica. 1987 ; Vol. 78, No. SUPPL. 1. pp. 175-180.
@article{2027d0d9a6ac41db894cd16508ea8dd5,
title = "Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences",
abstract = "Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56{\%}), 16/30 (53{\%}) and 4/17 (24{\%}), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (NALL) following busulfan (Bu) resulted in DFS and CR1, CR2 + CR3 + early relapse of 21/47 (45{\%}) and 13/41 (32{\%}), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56{\%}) and 19/61 (31{\%}) for ages 21-46. Three relapses of 47 (6{\%}) were seen in CR1 and 6/41 (15{\%}) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41{\%}) for 1-67 months (median 15 months). Twenty patients with prior risk non-Hodgkin's lymphoma received 4-HC-purged marrow following Cy + TBI. DFS was 10/20 (50{\%}) for 1.4-9.5 years (median 2.9 years).",
author = "Santos, {G. W.} and R. Saral and Burns, {W. H.} and Braine, {H. G.} and Sensenbrenner, {L. L.} and Wingard, {J. R.} and Yeager, {Andrew M} and R. Jones and Ambinder, {R. F.} and Rowley, {S. D.} and S. May and Vogelsang, {G. B.}",
year = "1987",
language = "English (US)",
volume = "78",
pages = "175--180",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences

AU - Santos, G. W.

AU - Saral, R.

AU - Burns, W. H.

AU - Braine, H. G.

AU - Sensenbrenner, L. L.

AU - Wingard, J. R.

AU - Yeager, Andrew M

AU - Jones, R.

AU - Ambinder, R. F.

AU - Rowley, S. D.

AU - May, S.

AU - Vogelsang, G. B.

PY - 1987

Y1 - 1987

N2 - Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56%), 16/30 (53%) and 4/17 (24%), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (NALL) following busulfan (Bu) resulted in DFS and CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56%) and 19/61 (31%) for ages 21-46. Three relapses of 47 (6%) were seen in CR1 and 6/41 (15%) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41%) for 1-67 months (median 15 months). Twenty patients with prior risk non-Hodgkin's lymphoma received 4-HC-purged marrow following Cy + TBI. DFS was 10/20 (50%) for 1.4-9.5 years (median 2.9 years).

AB - Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56%), 16/30 (53%) and 4/17 (24%), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (NALL) following busulfan (Bu) resulted in DFS and CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56%) and 19/61 (31%) for ages 21-46. Three relapses of 47 (6%) were seen in CR1 and 6/41 (15%) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41%) for 1-67 months (median 15 months). Twenty patients with prior risk non-Hodgkin's lymphoma received 4-HC-purged marrow following Cy + TBI. DFS was 10/20 (50%) for 1.4-9.5 years (median 2.9 years).

UR - http://www.scopus.com/inward/record.url?scp=0023555318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023555318&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 175

EP - 180

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - SUPPL. 1

ER -